Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0330264/Hepatitis-B-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global hepatitis b vaccines market. The report identifies the key trends shaping and driving the global hepatitis b vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis b vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the global hepatitis b vaccines market at $997.0m in 2010, and forecast it to grow at a compound annual growth rate (CAGR) of 4.1% for the next eight years, to reach $1,376.1m by 2018. During the period 2005–2010, the market grew at a CAGR of 6.7%, from $720.5m to $997.0. The growth is primarily attributed to the increase in the vaccination rate and coverage among different age groups, as a result of government programs and increased public awareness. The market would also be driven by birth population growth and the need for therapeutic vaccines in cases of cirrhosis, liver disease, and primary liver cancer (hepatocellular carcinoma or HCC).
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the hepatitis b vaccines market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) hepatitis b vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as single antigen vaccine, combinational vaccine and others.
- Analysis of the current and future competition in the seven key countries hepatitis b vaccines market. Key market players covered are Dynavax Technologies Ltd., Merck, GlaxoSmithKline, Sanofi, GenPhar, LG Life Sciences, Genexine and NanoBio Corp.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis b vaccines therapeutics market.
- Analysis of key recent licensing and partnership agreements in hepatitis b vaccines market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis b vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis b vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global hepatitis b vaccines market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 8
2 Hepatitis B Vaccines Market: Executive Summary 10
2.1 The Hepatitis B Vaccines Market is Forecast to Show Moderate Growth until 2018 10
2.2 The Highly Competitive Hepatitis B Vaccine Market is Capable of Catering to Most of the Market Needs 11
2.3 Late Stage Pipeline Molecules Would Not Lead to a Significant Impact in the Forecast Period 11
2.4 Significant Unmet Need Present in the Hepatitis B Vaccine Market 11
3 Hepatitis B: Introduction 13
3.1 Overview 13
3.2 Epidemiology 15
3.3 Etiology 18
3.4 Symptoms 19
3.5 Diagnosis 20
3.6 Pathophysiology 23
3.7 Treatment and Management Pattern 26
3.8 GlobalData Pipeline Report Guidance 30
4 Hepatitis B Vaccines Therapeutics: Market Characterization 31
4.1 Hepatitis B Vaccines Market Size (2005-2010) – Global 31
4.2 Hepatitis B Vaccines Market Forecast (2010-2018) – Global 32
4.3 Hepatitis B Vaccines Market Size (2005-2010) – The US 34
4.4 Hepatitis B Vaccines Market Forecast (2010-2018) – The US 35
4.5 Hepatitis B Vaccines Market Size (2005-2010) – France 36
4.6 Hepatitis B Vaccines Market Forecast (2010-2018) – France 38
4.7 Hepatitis B Vaccines Market Size (2005-2010) – Germany 40
4.8 Hepatitis B Vaccines Market Forecast (2010-2018) – Germany 41
4.9 Hepatitis B Vaccines Market Size (2005-2010) – Italy 43
4.10 Hepatitis B Vaccines Market Forecast (2010-2018) – Italy 45
4.11 Hepatitis B Vaccines Market Size (2005-2010) – Spain 47
4.12 Hepatitis B Vaccines Market Forecast (2010-2018) – Spain 48
4.13 Hepatitis B Vaccines Market Size (2005-2010) – The UK 50
4.14 Hepatitis B Vaccines Market Forecast (2010-2018) – The UK 51
4.15 Hepatitis B Vaccines Market Size (2005-2010) – Japan 53
4.16 Hepatitis B Vaccines Market Forecast (2010-2018) – Japan 54
4.17 Drivers and Barriers for the Hepatitis B Vaccines Market 55
4.17.1 Drivers for the Hepatitis B Vaccines Market 55
4.17.1.1 Increase in Population 55
4.17.1.2 Increased Vaccination Coverage by Implementation of Immunization Programs 55
4.17.1.3 Patient Affordability 55
4.17.2 Barriers for the Hepatitis B Vaccines Market 55
4.17.2.1 Screening Pattern of Hepatitis B 55
4.17.2.2 The Selective Vaccination Approach for Hepatitis B Infection 56
4.18 Opportunity and Unmet Need 56
4.19 Key Takeaway 58
5 Hepatitis B Vaccines Market: Competitive Assessment 59
5.1 Overview 59
5.2 Strategic Competitor Assessment 60
5.3 Product Profile for the Major Marketed Products in the Hepatitis B Vaccines Market 60
5.3.1 Recombivax HB 60
5.3.1.1 Overview 60
5.3.1.2 Efficacy 60
5.3.1.3 Safety 60
5.3.1.4 Clinical Study Details 60
5.3.1.5 Cost of Therapy 61
5.3.2 Engerix-B 61
5.3.2.1 Overview 61
5.3.2.2 Efficacy 61
5.3.2.3 Safety 61
5.3.2.4 Clinical Study Details 62
5.3.2.5 Cost of Therapy 62
5.3.3 Twinrix 62
5.3.3.1 Overview 62
5.3.3.2 Efficacy 62
5.3.3.3 Safety 62
5.3.3.4 Clinical Study Details 63
5.3.3.5 Cost of Therapy 63
5.3.4 Comvax 63
5.3.4.1 Overview 63
5.3.4.2 Efficacy 63
5.3.4.3 Safety 64
5.3.4.4 Clinical Study Details 64
5.3.4.5 Cost of Therapy 64
5.3.5 Pediarix 64
5.3.5.1 Overview 64
5.3.5.2 Efficacy 64
5.3.5.3 Safety 64
5.3.5.4 Clinical Study Details 64
5.3.5.5 Cost of Therapy 65
5.4 Major Marketed Products Comparison in the Hepatitis B Vaccines Market 65
5.5 Key Takeaway 67
6 Hepatitis B Vaccines: Pipeline Assessment 68
6.1 Overview 68
6.2 Strategic Pipeline Assessment 68
6.3 Hepatitis B Vaccines – Pipeline Analysis by Phase of Development 68
6.3.1 Hepatitis B Vaccines – Filed and Phase III Pipeline 68
6.3.2 Hepatitis B Vaccines – Phase II Pipeline 68
6.3.3 Hepatitis B Vaccines – Phase I Pipeline 69
6.3.4 Hepatitis B Vaccines – Pre-clinical and Discovery Pipeline 69
6.4 Hepatitis B Vaccines – Pipeline by Type of Vaccines 69
6.5 Technology Trends Analytical Framework 72
6.6 Most Promising Drug Profiles 74
6.6.1 Heplisav 74
6.6.1.1 Overview 74
6.6.1.2 Efficacy 74
6.6.1.3 Safety 74
6.6.1.4 Clinical Study Details 74
6.6.2 Hexaxim 75
6.6.2.1 Overview 75
6.6.2.2 Efficacy 75
6.6.2.3 Safety 75
6.6.2.4 Clinical Study Details 75
6.6.3 Pediatric Hexavalent Vaccine (V419) 75
6.6.3.1 Overview 75
6.6.3.2 Clinical Study Details 75
6.6.4 DTwP-HB-Hib (Recon) Vaccine 76
6.6.4.1 Overview 76
6.6.4.2 Clinical Study Details 76
6.7 Key Takeaway 76
7 Hepatitis B Vaccines: Clinical Trials Mapping 77
7.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 77
7.2 Clinical Trials by Phase of Clinical Development 78
7.3 Clinical Trials by Trial Status 79
7.4 Clinical Trials by Sponsors 79
7.5 Top Companies Participating in Hepatitis B Vaccines Clinical Trials 82
8 Hepatitis B Vaccines Market: Strategic Assessment 84
8.1 Key Events Impacting the Future Market 84
8.2 Future Market Competition Scenario 84
9 Hepatitis B Vaccines Market: Future Players 86
9.1 Introduction 86
9.2 Company Profiles 87
9.2.1 Sanofi 87
9.2.1.1 Overview 87
9.2.1.2 Financial Performance 87
9.2.1.3 Business Description 88
9.2.1.4 Vaccine Pipeline Portfolio 90
9.2.2 GlaxoSmithKline 90
9.2.2.1 Overview 90
9.2.2.2 Financial Description 91
9.2.2.3 Business Description 91
9.2.2.4 Vaccine Pipeline Portfolio 92
9.2.3 Dynavax Technologies Corporation 93
9.2.3.1 Overview 93
9.2.3.2 Financial Description 93
9.2.3.3 Business Description 94
9.2.3.4 Vaccine Pipeline Portfolio 94
9.2.4 LG Life Sciences Ltd 94
9.2.4.1 Overview 94
9.2.4.2 Financial performance 95
9.2.4.3 Business overview 95
9.2.4.4 Vaccine Pipeline Portfolio 95
9.2.5 Merck & Co., Inc. 96
9.2.5.1 Company Overview 96
9.2.5.2 Financial Overview 96
9.2.5.3 Business Description 96
9.2.5.4 Vaccine Pipeline Portfolio 97
9.3 Details of Other Companies in the Pipeline 97
9.4 Key Takeaway 100
10 Hepatitis B Vaccines: Licensing and Partnership Deals 101
11 Hepatitis B Vaccines: Appendix 102
11.1 Definitions 102
11.2 Acronyms 102
11.3 Research Methodology 104
11.3.1 Coverage 104
11.3.2 Secondary Research 104
11.3.3 Forecasting 105
11.3.3.1 Epidemiology-based Forecasting 105
11.3.4 Primary Research 108
11.3.5 Expert Panel Validation 109
11.4 Contact Us 109
11.5 Disclaimer 109
11.6 Bibliography 110
List of Tables
Table 1: Hepatitis B – Nomenclature of Hepatitis B 14
Table 2: Hepatitis B – Laboratory Nomenclature 22
Table 3: Hepatitis B – Approved Vaccines for Hepatitis B 27
Table 4: Hepatitis B – Approved Drugs for Hepatitis B 27
Table 5: Hepatitis B Vaccines Market, Global, Revenue ($m), 2005–2010 32
Table 6: Hepatitis B Vaccines Market, Global, Forecast ($m), 2010–2018 33
Table 7: Hepatitis B Vaccines Market, The US, Revenue ($m), 2005–2010 35
Table 8: Hepatitis B Vaccines Market, The US, Forecast ($m), 2010–2018 36
Table 9: Hepatitis B Vaccines Market, France, Revenue ($m), 2005–2010 38
Table 10: Hepatitis B Vaccines Market, France, Forecast ($m), 2010–2018 40
Table 11: Hepatitis B Vaccines Market, Germany, Revenue ($m), 2005–2010 41
Table 12: Hepatitis B Vaccines Market, Germany, Forecast ($m), 2010–2018 43
Table 13: Hepatitis B Vaccines Market, Italy, Revenue ($m), 2005–2010 45
Table 14: Hepatitis B Vaccines Market, Italy, Forecast ($m), 2010–2018 46
Table 15: Hepatitis B Vaccines Market, Spain, Revenue ($m), 2005–2010 48
Table 16: Hepatitis B Vaccines Market, Spain, Forecast ($m), 2010–2018 49
Table 17: Hepatitis B Vaccines Market, The UK, Revenue ($m), 2005–2010 51
Table 18: Hepatitis B Vaccines Market, The UK, Forecast ($m), 2010–2018 52
Table 19: Hepatitis B Vaccines Market, Japan, Revenue ($m), 2005–2010 53
Table 20: Hepatitis B Vaccines Market, Japan, Forecast ($m), 2010–2018 54
Table 21: Antibody Responses Following PEDIARIX as Compared to Separate Concomitant Administration of INFANRIX, ENGERIX-B, and IPV (One Month After Administration of Dose 3) 65
Table 22: Hepatitis B Vaccines Market, Global, Major Marketed Products Comparison, 2011 65
Table 23: Hepatitis B Vaccines – Filed and Phase III Clinical Pipeline, 2011 68
Table 24: Hepatitis B Vaccines – Phase II Clinical Pipeline, 2011 68
Table 25: Hepatitis B Vaccines – Phase I Clinical Pipeline, 2011 69
Table 26: Hepatitis B Vaccines – Pre-Clinical and Discovery Pipeline, 2011 69
Table 27: Hepatitis B Vaccines, Global, Clinical Trials, 2011 77
Table 28: Hepatitis B Vaccines, Global, Clinical Trials by Phase, 2011 78
Table 29: Hepatitis B Vaccines, Global, Clinical Trials by Status of Development, 2011 79
Table 30: Hepatitis B Vaccines, Global, Overall Sponsors, 2011 80
Table 31: Hepatitis B Vaccines, Global, Prominent Sponsors, 2011 81
Table 32: Hepatitis B Vaccines, Global, Top Ten Companies by Phase, 2011 82
Table 33: Sanofi - Vaccines Pipeline Portfolio, 2011 90
Table 34: GlaxoSmithKline - Vaccines Pipeline Portfolio, 2011 93
Table 35: Dynavax Technologies Corporation – Vaccine Pipeline Products, 2011 94
Table 36: LG Life Sciences – Vaccines Pipeline Portfolio, 2011 96
Table 37: Merck & Co., Inc. – Vaccine Pipeline Portfolio, 2011 97
Table 38: Description of Other Companies in the Pipeline, 2011 98
Table 39: Hepatitis B Vaccines, Global, Deals, 2011 101
List of Figures
Figure 1: Hepatitis B Vaccines, Global, Revenue and Market Forecast ($m), 2005–2018 10
Figure 2: Opportunity and Unmet Need in the Hepatitis B Vaccines Market, 2011 12
Figure 3: Structure of Hepatitis B Virus 13
Figure 4: Genotype of Hepatitis B Virus and its Geographical Distribution 14
Figure 5: Summary of Hepatitis B Virus Characteristics 15
Figure 6: Hepatitis B – Prevalence of HBV Infection in the World by Country 16
Figure 7: Hepatitis B – Areas and Features of Hepatitis B Prevalence 17
Figure 8: Geographic Patterns of Hepatitis B Disease Burden 18
Figure 9: Hepatitis B – Interpretation of Hepatitis B Virus Serology 23
Figure 10: Hepatitis B – Life Cycle of HBV 25
Figure 11: Hepatitis B – Spectrum of Liver Disease After HBV Infection 26
Figure 12: Hepatitis B – Childhood Vaccination Schedule 29
Figure 13: Hepatitis B Vaccines Market, Global, Revenue ($m), 2005–2010 31
Figure 14: Hepatitis B Vaccines Market, Global, Forecast ($m), 2010–2018 33
Figure 15: Hepatitis B Vaccines Market, The US, Revenue ($m), 2005–2010 34
Figure 16: Hepatitis B Vaccines Market, The US, Forecast ($m), 2010–2018 35
Figure 17: Hepatitis B Vaccines Market, France, Revenue ($m), 2005–2010 36
Figure 18: Hepatitis B Vaccines Market, France, Forecast ($m), 2010–2018 38
Figure 19: Hepatitis B Vaccines Market, Germany, Revenue ($m), 2005–2010 40
Figure 20: Hepatitis B Vaccines Market, Germany, Forecast ($m), 2010–2018 41
Figure 21: Hepatitis B Vaccines Market, Italy, Revenue ($m), 2005–2010 43
Figure 22: Hepatitis B Vaccines Market, Italy, Forecast ($m), 2010–2018 46
Figure 23: Hepatitis B Vaccines Market, Spain, Revenue ($m), 2005–2010 47
Figure 24: Hepatitis B Vaccines Market, Spain, Forecast ($m), 2010–2018 48
Figure 25: Hepatitis B Vaccines Market, The UK, Revenue ($m), 2005–2010 50
Figure 26: Hepatitis B Vaccines Market, The UK, Forecast ($m), 2010–2018 51
Figure 27: Hepatitis B Vaccines Market, Japan, Revenue ($m), 2005–2010 53
Figure 28: Hepatitis B Vaccines Market, Japan, Forecast ($m), 2010–2018 54
Figure 29: Opportunity and Unmet Need in the Hepatitis B Vaccines Market, 2011 57
Figure 30: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Vaccines, 2011 59
Figure 31: Hepatitis B Vaccines, Clinical Pipeline by Mechanism of Action (%), 2011 70
Figure 32: Hepatitis B Vaccines – Clinical Pipeline by Phase of Development (%), 2011 71
Figure 33: Technology Trends Analytics Framework, 2011 72
Figure 34: Technology Trends Analytical Framework – Description, 2011 73
Figure 35: Hepatitis B Vaccines, Global, Clinical Trials by Country, 2011 77
Figure 36: Hepatitis B Vaccines, Global, Clinical Trials by Phase (%), 2011 78
Figure 37: Hepatitis B Vaccines, Global, Clinical Trials by Status of Development (%), 2011 79
Figure 38: Hepatitis B Vaccines, Global, Overall Sponsors (%), 2011 80
Figure 39: Hepatitis B Vaccines, Global, Prominent Sponsors (%), 2011 81
Figure 40: Hepatitis B Vaccines, Global, Top Companies by Phase, 2011 82
Figure 41: Hepatitis B Vaccines Market, Drivers and Barriers, 2011 84
Figure 42: Implications for Future Market Competition in the Hepatitis B Vaccines Market, 2011 85
Figure 43: Hepatitis B Vaccines Market, Clinical Pipeline by Company, 2011 87
Figure 44: GlobalData Market Forecasting Model 108Sanofi
GlaxoSmithKline
Dynavax Technologies Corporation
LG Life Sciences Ltd
Merck & Co., Inc.
To order this report:
Drug and Medication Industry: Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article